| Full description or abstract |
We aimed to define the proteomic signature of bone marrow (BM) extracellular matrices (ECMs) obtained from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM), as compared with healthy donor-derived BM ECMs. We have applied a novel proteomic-based strategy and defined the BM ECM composition in patients with MGUS, newly diagnosed and relapsed MM, compared with healthy donor-derived BM ECM. Peptide abundance, spectral count, number of unique peptides, and the number of identified proteins within the whole BM were measured for both healthy donors and patients with MGUS or MM, either at first diagnosis or at relapse. We began by defining the matrisome of healthy donor-derived BM as the ensemble of proteins detected in at least three independent biological replicates (that is, patients) and by at least three peptides in one of the replicates. Subsequently, we sought to define the proteomic signature for BM ECMs derived from MGUS patients using the same criteria. Comparing the these matrisomes identified proteins expressed by all four groups as well as proteins that are not present until later stages of the disease. This gene set lists the matrisome proteins detected in newly-diagnosed MM patient BM compared to MGUS and relapsed MM-BM. |
| Source publication |
Pubmed 28344315 Authors: Glavey SV,Naba A,Manier S,Clauser K,Tahri S,Park J,Reagan MR,Moschetta M,Mishima Y,Gambella M,Rocci A,Sacco A,O'Dwyer ME,Asara JM,Palumbo A,Roccaro AM,Hynes RO,Ghobrial IM |
